PMID- 15269135
OWN - NLM
STAT- MEDLINE
DCOM- 20050119
LR  - 20181130
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 10
IP  - 14
DP  - 2004 Jul 15
TI  - Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in 
      primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant 
      trial.
PG  - 4639-44
AB  - PURPOSE: Many studies suggest that Her2/neu play an important role in neoadjuvant 
      endocrine therapy. This study aimed to determine whether the level of Her2/neu 
      expression in advanced breast cancer changes after antiaromatase neoadjuvant 
      treatment, as well as to identify the relationship between Her2/neu expression 
      and response to this kind of therapy. EXPERIMENTAL DESIGN: Thirty-six 
      postmenopausal patients with hormonal receptor-positive primary breast cancer 
      were included in a study of three monthly cycles of neoadjuvant endocrine therapy 
      with either Aromasin (25 mg daily) or Femara (2.5 mg daily). Immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH) for Her2/neu were conducted 
      both on pretreatment biopsies and surgical tumors. RESULTS: Using IHC, 5 of 36 
      (13.9%) of the patients had a Her2/neu overexpression after treatment, as 
      compared with 16 of 36 (44.4%) before. Meanwhile, there was no change in 21 
      (58.3%) patients, and through FISH, there was a change from amplification to no 
      amplification in 15 (41.7%) patients. The response rate to the treatment was 75% 
      for Her2/neu (+) tumors and 35% for Her2/neu (-) tumors (P = 0.017) while FISH 
      was performed. The response rate was also significantly affected by the decrease 
      in Her2/neu status after the treatment, with 73% of the tumors showing decreased 
      Her2/neu expression and with 38% of the tumors showing no change of Her2/neu 
      expression (P = 0.037). CONCLUSIONS: Using both IHC and FISH, advanced breast 
      cancers show statistical evidence of decreasing incidence of Her2/neu expression 
      after antiaromatase neoadjuvant treatment. Our data also suggest that Her2/neu 
      expression and its change during the treatment might be predictive markers for 
      this kind of therapy.
FAU - Zhu, Li
AU  - Zhu L
AD  - Department of Surgery, The University of Hong Kong, Hong Kong, China.
FAU - Chow, Louis W C
AU  - Chow LW
FAU - Loo, Wings T Y
AU  - Loo WT
FAU - Guan, Xin-Yuan
AU  - Guan XY
FAU - Toi, Mazakazu
AU  - Toi M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Androstadienes)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Nitriles)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 0 (Triazoles)
RN  - 7LKK855W8I (Letrozole)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - JCX84Q7J1L (Celecoxib)
RN  - NY22HMQ4BX (exemestane)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Androstadienes/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Aromatase Inhibitors/*therapeutic use
MH  - Breast Neoplasms/genetics/metabolism/*therapy
MH  - Celecoxib
MH  - Cyclooxygenase Inhibitors/therapeutic use
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Letrozole
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Nitriles/therapeutic use
MH  - Prognosis
MH  - Pyrazoles/therapeutic use
MH  - Receptor, ErbB-2/analysis/*genetics
MH  - Sulfonamides/therapeutic use
MH  - Treatment Outcome
MH  - Triazoles/therapeutic use
EDAT- 2004/07/23 05:00
MHDA- 2005/01/20 09:00
CRDT- 2004/07/23 05:00
PHST- 2004/07/23 05:00 [pubmed]
PHST- 2005/01/20 09:00 [medline]
PHST- 2004/07/23 05:00 [entrez]
AID - 10/14/4639 [pii]
AID - 10.1158/1078-0432.CCR-04-0057 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2004 Jul 15;10(14):4639-44. doi: 10.1158/1078-0432.CCR-04-0057.